United States Drug Patent 5,510,353: Scope, Claims, and Landscape Analysis
United States Patent 5,510,353, granted on April 23, 1996, to Applied Molecular Genetics, Inc. (Amgen), covers "IL-1ra Binding Proteins." This patent describes and claims proteins that bind to Interleukin-1 receptor antagonist (IL-1ra). The primary disclosed embodiment is a modified form of naturally occurring IL-1ra, designated as "Met-IL-1ra" or "AMGN-0122." The patent's claims are broad, encompassing purified IL-1ra binding proteins, antibodies to these proteins, and methods of treating inflammatory diseases using these proteins. The patent landscape surrounding IL-1ra and its inhibitors is characterized by extensive research and development by multiple pharmaceutical companies, with significant patent activity focused on various therapeutic applications, particularly in autoimmune and inflammatory conditions.
What is the Core Invention of Patent 5,510,353?
The invention disclosed in U.S. Patent 5,510,353 centers on modified proteins that interact with Interleukin-1 receptor antagonist (IL-1ra). IL-1ra is a naturally occurring protein that inhibits the biological activity of Interleukin-1 (IL-1), a pro-inflammatory cytokine. The patent describes the identification, isolation, and characterization of proteins that bind to IL-1ra.
The most significant aspect of the invention is the detailed description of a specific recombinant protein, Met-IL-1ra. This is a modified version of human IL-1ra where an additional methionine amino acid is present at the N-terminus. This modification is stated to enhance stability and facilitate expression in recombinant systems. The patent claims cover these binding proteins, including Met-IL-1ra, as well as antibodies that specifically bind to these IL-1ra binding proteins.
What are the Key Claims of Patent 5,510,353?
The claims of U.S. Patent 5,510,353 define the legal scope of the invention. They are crucial for understanding what activities are protected. The patent contains several independent and dependent claims. Key claims include:
- Claim 1: A purified protein which binds to human Interleukin-1 receptor antagonist (IL-1ra). This is a broad claim encompassing any isolated protein with the specified binding characteristic.
- Claim 7: A purified protein which binds to human IL-1ra, which protein is Met-IL-1ra, having the amino acid sequence set forth in SEQ ID NO: 2. This claim specifically covers the modified IL-1ra, Met-IL-1ra, with a defined amino acid sequence. SEQ ID NO: 2 corresponds to the N-terminal methionine-containing human IL-1ra.
- Claim 12: An antibody which binds specifically to a protein of claim 1. This claim extends protection to antibodies that target the IL-1ra binding proteins described in the patent.
- Claim 15: A method of treating a mammal for an inflammatory disease which comprises administering to said mammal an effective amount of a protein of claim 1. This claim covers the therapeutic use of IL-1ra binding proteins for treating inflammatory conditions.
The claims are designed to protect both the specific molecule (Met-IL-1ra) and broader categories of IL-1ra binding proteins, as well as the antibodies and therapeutic uses associated with them. The phrase "purified protein" is significant, as it requires the protein to be isolated from its natural environment and not in its naturally occurring mixture.
What is the Background of the Invention and Prior Art?
The invention arose from extensive research into the role of Interleukin-1 (IL-1) in inflammatory and immune responses. IL-1 is a key mediator of inflammation, contributing to various disease processes, including rheumatoid arthritis, inflammatory bowel disease, and sepsis. IL-1ra is a naturally occurring inhibitor of IL-1, acting by binding to the IL-1 receptor and preventing IL-1 signaling.
Prior art would have included knowledge of IL-1, IL-1ra, and their roles in disease. Research into recombinant protein production and antibody development would also constitute prior art. The novelty of this invention lies in the identification and characterization of specific modified IL-1ra proteins with improved properties for therapeutic development, such as Met-IL-1ra, and potentially other novel IL-1ra binding proteins. The patent likely aimed to secure intellectual property rights around a specific therapeutic agent and its related technologies that had potential commercial value for treating IL-1-mediated diseases.
Who is the Assignee of Patent 5,510,353?
The assignee of U.S. Patent 5,510,353 is Applied Molecular Genetics, Inc. (Amgen). Amgen is a leading biotechnology company known for its pioneering work in recombinant DNA technology and the development of biologic therapeutics. The assignment indicates that Amgen sponsored the research leading to this patent and holds the exclusive rights to the invention.
What are the Key Therapeutic Areas Addressed by the Patent?
The patent explicitly addresses the treatment of inflammatory diseases. This is a broad category encompassing conditions driven by excessive or dysregulated inflammatory responses. Examples relevant to IL-1 biology and thus potentially covered by this patent include:
- Rheumatoid arthritis
- Osteoarthritis
- Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- Sepsis
- Psoriasis and psoriatic arthritis
- Gout
- Ankylosing spondylitis
The therapeutic method claims (e.g., Claim 15) assert that the IL-1ra binding proteins can be administered to treat mammals suffering from such conditions.
What is the Commercial Significance of IL-1ra and its Inhibitors?
Interleukin-1 inhibitors, including IL-1ra, have significant commercial value due to their efficacy in treating chronic and debilitating inflammatory diseases. The market for biologic drugs targeting inflammatory pathways is substantial, driven by the high prevalence of conditions like rheumatoid arthritis.
Amgen's development of Met-IL-1ra (which later became known as anakinra, marketed as Kineret) was a notable advancement. Anakinra is a recombinant, non-glycosylated form of human IL-1ra that is administered by subcutaneous injection. It acts as a competitive antagonist of IL-1 receptors, blocking the pro-inflammatory actions of IL-1. Kineret was approved by the U.S. Food and Drug Administration (FDA) in 2001 for the treatment of moderate to severe active rheumatoid arthritis in patients who have responded inadequately to disease-modifying antirheumatic drugs.
The commercial success of anakinra, and the ongoing research into other IL-1 inhibitors, underscores the therapeutic and economic importance of targeting the IL-1 pathway. Patents like 5,510,353 are foundational to securing market exclusivity and recouping significant R&D investments in this competitive space.
What is the Patent Landscape Surrounding IL-1ra Inhibitors?
The patent landscape for IL-1ra inhibitors is extensive and highly competitive, involving multiple major pharmaceutical and biotechnology companies. Key aspects of this landscape include:
- Early Innovators: Amgen was an early innovator with patents like 5,510,353, which protected their specific recombinant IL-1ra molecule and related intellectual property.
- Competitor Patents: Other companies have developed and patented different IL-1ra inhibitors, including monoclonal antibodies that target IL-1alpha, IL-1beta, or the IL-1 receptor. Examples include:
- Humira (adalimumab) by AbbVie: Targets TNF-alpha, another key inflammatory cytokine, but addresses similar inflammatory diseases.
- Enbrel (etanercept) by Amgen/Pfizer: A TNF receptor fusion protein.
- Actemra (tocilizumab) by Genentech/Roche: Targets the IL-6 receptor.
- Canakinumab (Ilaris) by Novartis: A monoclonal antibody targeting IL-1beta.
- Second-Generation Therapies: The focus has shifted towards developing more targeted, potent, and convenient delivery methods for IL-1 inhibitors. This includes long-acting formulations and orally administered small molecules that inhibit IL-1 production or signaling.
- Patent Expirations and Generics: As patents for early-generation IL-1 inhibitors expire, opportunities arise for biosimilar and generic versions, increasing market competition and potentially lowering prices. However, patent thickets and new patent filings can extend market exclusivity.
- New Indications: Ongoing research seeks to identify new therapeutic uses for existing IL-1 inhibitors and to develop novel inhibitors for a wider range of inflammatory and autoimmune conditions, as well as conditions like cardiovascular disease and neurodegenerative disorders where IL-1 plays a role.
- Intellectual Property Strategies: Companies employ various strategies, including filing patents on novel compounds, formulations, manufacturing processes, and new uses, to maintain a strong IP position in this therapeutic area.
The patent landscape is dynamic, with ongoing litigation, licensing agreements, and new patent filings shaping the competitive environment. Companies must carefully navigate this complex terrain to develop and commercialize new therapies.
How Does Patent 5,510,353 Fit into Amgen's Portfolio?
Patent 5,510,353 is a foundational patent for Amgen's development of anakinra (Kineret). It covers the core composition of matter for their recombinant IL-1ra, which is the active pharmaceutical ingredient in Kineret. This patent would have provided Amgen with significant market exclusivity during its term, allowing them to recoup their R&D investment and establish a market presence in the anti-inflammatory drug sector.
While anakinra has faced competition from other biologics targeting different inflammatory pathways and from newer IL-1 inhibitors, this patent represents a key early step in Amgen's strategy to leverage biotechnology to address significant unmet medical needs. The intellectual property secured by this patent would have been critical in the early commercialization and market entry of their IL-1ra therapy.
What are the Potential Legal Challenges and Infringement Considerations?
Patents like 5,510,353 can face legal challenges, including:
- Invalidity Challenges: Competitors may challenge the patent's validity based on prior art that was not considered by the patent office during prosecution, arguing that the invention was not novel or was obvious.
- Infringement Litigation: If a competitor develops a product that falls within the scope of one or more claims of the patent, the patent holder can initiate an infringement lawsuit. This often involves complex legal and technical arguments to determine if the competitor's product directly infringes, indirectly infringes, or induces infringement of the patent claims.
- Claim Construction Disputes: During litigation, courts must interpret the meaning and scope of patent claims. Disputes over claim construction are common and can significantly impact the outcome of infringement cases.
For companies developing IL-1ra inhibitors, careful freedom-to-operate (FTO) analysis is essential to ensure their products do not infringe on existing patents. This involves a thorough review of granted patents and pending applications in the relevant therapeutic area.
Key Takeaways
- U.S. Patent 5,510,353, assigned to Amgen, protects IL-1ra binding proteins, specifically a modified recombinant form known as Met-IL-1ra (which became the active ingredient in anakinra/Kineret).
- The patent's claims cover the purified proteins, antibodies to these proteins, and methods of treating inflammatory diseases using these proteins.
- The invention targets the IL-1 pathway, a critical mediator of inflammation, with applications in conditions like rheumatoid arthritis.
- The patent represents a foundational intellectual property asset for Amgen's development and commercialization of anakinra.
- The patent landscape for IL-1ra inhibitors is crowded and competitive, involving multiple pharmaceutical companies and a range of therapeutic strategies, from early recombinant proteins to monoclonal antibodies and potentially future oral treatments.
Frequently Asked Questions
1. What is the specific amino acid sequence claimed in U.S. Patent 5,510,353?
The patent references SEQ ID NO: 2, which corresponds to the amino acid sequence of human IL-1ra with an N-terminal methionine. While the patent text itself does not directly display the full sequence, it is referenced as the defining characteristic of the claimed Met-IL-1ra.
2. Does this patent cover all inhibitors of Interleukin-1?
No, this patent specifically covers proteins that bind to Interleukin-1 receptor antagonist (IL-1ra) and antibodies to these binding proteins, not all possible mechanisms of inhibiting Interleukin-1 itself or its signaling pathway.
3. What is the expiration date of U.S. Patent 5,510,353?
As a utility patent granted in 1996, U.S. Patent 5,510,353 would have had an initial term of 20 years from its filing date. Assuming a filing date in the early 1990s, its primary term has expired. However, extensions or related patents could exist.
4. Can Amgen still enforce this patent today?
Given its grant date in 1996, the original term of this specific patent has likely expired. Therefore, Amgen would not typically be able to enforce the claims of this particular patent against new products for its remaining term. Enforcement would be limited to any unexpired patents within its portfolio related to anakinra or its use.
5. What is the relationship between this patent and the drug anakinra (Kineret)?
U.S. Patent 5,510,353 is a foundational patent that covers the composition of matter for the active pharmaceutical ingredient (API) in anakinra, which is a recombinant form of IL-1ra (specifically, Met-IL-1ra). This patent provided the initial intellectual property protection for Amgen's development of this therapeutic.
Citations
[1] Applied Molecular Genetics, Inc. (1996). US Patent 5,510,353: IL-1ra Binding Proteins. United States Patent and Trademark Office.
